Table 1.
Clinical Characteristics of Modeling and Validation Cohorts
| Characteristic | Modeling Cohort |
Validation Cohort |
||
|---|---|---|---|---|
| No. | % | No. | % | |
| Patients | 6,398 | 6,279 | ||
| Age, years | ||||
| Median | 61 | 60 | ||
| IQR | 56-66 | 55-65 | ||
| PSA, ng/mL | ||||
| Median | 6.3 | 6.0 | ||
| IQR | 4.4-9.5 | 4.5-8.8 | ||
| Biopsy Gleason score | ||||
| 2-6 | 4,126 | 64 | 3,825 | 61 |
| 7 | 1,787 | 28 | 1,832 | 29 |
| 8-10 | 403 | 6 | 356 | 6 |
| Missing value | 82 | 1 | 266 | 4 |
| Clinical stage | ||||
| T1ab | 147 | 2 | 57 | 1 |
| T1c | 2,700 | 42 | 4,035 | 64 |
| T2a | 1,242 | 19 | 1,358 | 22 |
| T2b | 1,119 | 18 | 426 | 7 |
| T2c | 568 | 9 | 178 | 3 |
| T3 | 244 | 4 | 47 | 1 |
| Missing value | 378 | 6 | 178 | 3 |
| Neoadjuvant ADT | 809 | 13 | 397 | 6 |
| Year of surgery | ||||
| 1987-1990 | 488 | 8 | 348 | 6 |
| 1991-1998 | 2,442 | 38 | 1,782 | 28 |
| 1999-2005 | 3,468 | 54 | 4,149 | 66 |
| Postoperative pelvic radiation therapy | 115 | 2 | 538 | 8 |
| Postoperative androgen deprivation therapy | 426 | 7 | 343 | 6 |
| Death from prostate cancer | 117 | 2 | 98 | 2 |
| Death from competing causes | 343 | 5 | 343 | 6 |
| Follow-up, months | ||||
| Median | 48 | 54 | ||
| IQR | 18-90 | 24-99 | ||
Abbreviations: IQR, interquartile range; PSA, prostate-specific antigen; ADT, androgen deprivation therapy.